Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 4Not yet recruiting 4Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3CNS 1

Conditions

Breast Neoplasms 115Carcinoma, Non-Small-Cell Lung 103Prostatic Neoplasms 90Neoplasms 74Multiple Myeloma 73Lung Neoplasms 64Colorectal Neoplasms 50Leukemia, Myeloid, Acute 46Neoplasm Metastasis 43Lymphoma 39Pancreatic Neoplasms 38Melanoma 38Lymphoma, Non-Hodgkin 36Carcinoma, Renal Cell 36Ovarian Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Squamous Cell Carcinoma of Head and Neck 31Urinary Bladder Neoplasms 30Hematologic Neoplasms 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Endometrial Neoplasms 26Uterine Cervical Neoplasms 25Carcinoma, Hepatocellular 25Triple Negative Breast Neoplasms 24Sarcoma 24Glioma 24Stomach Neoplasms 22Head and Neck Neoplasms 22Lymphoma, Large B-Cell, Diffuse 21Brain Neoplasms 21

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 2pembrolizumab 1dehydroftorafur 1atezolizumab 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Diffusion Tensor Imaging 1Colonoscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Neoplasms, Hereditary Nonpolyposis × 30 days × Clear all
NCT02912559 2026-06-01

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

Phase 3 Active not recruiting
712 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT05419011 2026-05-27

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

National Cancer Institute (NCI)

Phase 2 Active not recruiting
186 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡